LYEL vs FATE vs ADCT

For growth investors, ADC Therapeutics S.

A. (ADCT) is the stronger pick with 14. 9% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Analysts rate Fate Therapeutics, Inc. (FATE) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ADC Therapeutics S.

A. (ADCT) delivered a total return of -84. 4%, compared to -96. 8% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: FATE returned +38. 2% versus LYEL's -94. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lyell Immunopharma, Inc.

(LYEL) is the lower-risk stock at 1. 83β versus Fate Therapeutics, Inc. 's 1. 99β — meaning FATE is approximately 9% more volatile than LYEL relative to the S&P 500. On balance sheet safety, Lyell Immunopharma, Inc. (LYEL) carries a lower debt/equity ratio of 17% versus 38% for Fate Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ADC Therapeutics S.

A. (ADCT) is pulling ahead at 14. 9% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: ADC Therapeutics S. A. grew EPS 30. 9% year-over-year, compared to -1126. 0% for Lyell Immunopharma, Inc.. Over a 3-year CAGR, ADCT leads at -27. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ADC Therapeutics S.

A. (ADCT) is the more profitable company, earning -175. 3% net margin versus -7623. 6% for Lyell Immunopharma, Inc. — meaning it keeps -175. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADCT leads at -133. 2% versus -5660. 4% for LYEL. At the gross margin level — before operating expenses — ADCT leads at 90. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Lyell Immunopharma, Inc.

(LYEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Fate Therapeutics, Inc. (FATE) carries a higher beta of 1. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LYEL: -94. 3%, FATE: +38. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.